Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AdvisorShares Psychedelics ETF (NY:PSIL)

16.69 -0.42 (-2.45%)
Official Closing Price Updated: 4:10 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,394
Open 17.31
Bid (Size) 16.25 (200)
Ask (Size) 24.87 (100)
Prev. Close 17.11
Today's Range 16.69 - 17.31
52wk Range 9.580 - 21.61
Shares Outstanding 7,499
Dividend Yield 40.36%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? ↗
Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge. 
Via Stocktwits
Topics ETFs
News headline image
Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order ↗
Jefferies sees restrictions around non-recreational psychedelics eventually loosen up. 
Via Stocktwits
Topics Cannabis ETFs Government

Performance

YTD
-3.0%
-3.0%
1 Month
-2.4%
-2.4%
3 Month
-15.5%
-15.5%
6 Month
-0.3%
-0.3%
1 Year
+34.1%
+34.1%

More News

Read More
News headline image
Why Did KTTA Stock Soar A Whopping 48% Today? ↗
Via Stocktwits
NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition ↗
Via Stocktwits
News headline image
Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug ↗
Via Benzinga
News headline image
Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts ↗
Via Stocktwits
News headline image
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors ↗
Via Benzinga
Topics Government
News headline image
5 ETFs That Beat Market Turmoil With Gains Last Week ↗
Via Benzinga
Topics ETFs Economy
News headline image
High-Momentum ETFs Leading the Market This Year
Via MarketBeat
Topics ETFs
News headline image
Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding ↗
Via Stocktwits
News headline image
Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish ↗
Via Stocktwits
News headline image
5 Best-Performing Sector ETFs Of Q4 ↗
Via Talk Markets
Topics ETFs
News headline image
Why Is Penny Stock Clearmind Gaining Today? ↗
Via Benzinga
News headline image
5 Best-Performing Sector ETFs Midway In Q4 ↗
Via Talk Markets
Topics ETFs
News headline image
Top And Flop ETFs Of The First Half ↗
Via Talk Markets
Topics ETFs
News headline image
Best And Worst ETF Zones Of Q2 ↗
Via Talk Markets
Topics Artificial Intelligence ETFs Economy
News headline image
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment ↗
Via Benzinga
News headline image
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗
Via Benzinga
News headline image
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗
Via Benzinga
News headline image
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗
Via Benzinga
Topics Economy
News headline image
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗
Via Benzinga
News headline image
Mental Health Mavericks: 3 Stocks Changing the Game ↗
Via InvestorPlace
News headline image
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗
Via Benzinga
News headline image
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗
Via Benzinga
News headline image
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗
Via Benzinga

Frequently Asked Questions

Is AdvisorShares Psychedelics ETF publicly traded?
Yes, AdvisorShares Psychedelics ETF is publicly traded.
What exchange does AdvisorShares Psychedelics ETF trade on?
AdvisorShares Psychedelics ETF trades on the New York Stock Exchange
What is the ticker symbol for AdvisorShares Psychedelics ETF?
The ticker symbol for AdvisorShares Psychedelics ETF is PSIL on the New York Stock Exchange
What is the current price of AdvisorShares Psychedelics ETF?
The current price of AdvisorShares Psychedelics ETF is 16.69
When was AdvisorShares Psychedelics ETF last traded?
The last trade of AdvisorShares Psychedelics ETF was at 01/30/26 04:10 PM ET
What is the market capitalization of AdvisorShares Psychedelics ETF?
The market capitalization of AdvisorShares Psychedelics ETF is 125.16K
How many shares of AdvisorShares Psychedelics ETF are outstanding?
AdvisorShares Psychedelics ETF has 125K shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.